Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III…
Marks GSK’s fourth Breakthrough Therapy designation London, UK, 17-1-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE: GSK) announced today that the U.S.…